Binding of S-citalopram and paroxetine discriminates between species.

Synapse

Laboratory of Molecular Neurobiology, Department of Biological Psychiatry, Aarhus Psychiatric University Hospital, Risskov, Denmark.

Published: March 2005

Download full-text PDF

Source
http://dx.doi.org/10.1002/syn.20116DOI Listing

Publication Analysis

Top Keywords

binding s-citalopram
4
s-citalopram paroxetine
4
paroxetine discriminates
4
discriminates species
4
binding
1
paroxetine
1
discriminates
1
species
1

Similar Publications

Changes in hippocampal volume, 5-HT receptor binding, and verbal memory over the course of antidepressant treatment in major depressive disorder.

J Psychiatr Res

November 2024

Neurobiology Research Unit and BrainDrugs, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Mental Health Center Copenhagen, Copenhagen University Hospital - Mental Health Services CPH, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Article Synopsis
  • - Serotonin reuptake inhibitors may help boost memory and increase hippocampal volume in patients with Major Depressive Disorder (MDD), particularly through the involvement of the 5-HT4 receptor. - In a study with 91 patients, significant reductions in hippocampal volume were observed after 8 weeks of treatment, especially in those responding well to the antidepressant escitalopram. - The research indicated a negative relationship between 5-HT4 receptor binding and hippocampal volume in females, suggesting a complex interaction that needs further exploration to understand its impact on memory and brain plasticity in MDD.
View Article and Find Full Text PDF

Effect of Antidepressant Treatment on 5-HT Receptor Binding and Associations With Clinical Outcomes and Verbal Memory in Major Depressive Disorder.

Biol Psychiatry

February 2025

Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Psychiatric Center Copenhagen, Copenhagen, Denmark. Electronic address:

Background: Brain serotonin 4 receptor (5-HTR) levels are lower in untreated patients with major depressive disorder (MDD) and are linked to verbal memory. Here, we investigated the relationship between 5-HTR levels, clinical outcomes, and cognitive function in patients with MDD who initiated selective serotonin reuptake inhibitor drug treatment.

Methods: Ninety patients with moderate to severe depression underwent molecular brain imaging to measure 5-HTR binding prior to antidepressant treatment with escitalopram.

View Article and Find Full Text PDF

Molecular basis of human noradrenaline transporter reuptake and inhibition.

Nature

August 2024

Beijing Frontier Research Center for Biological Structure, State Key Laboratory of Membrane Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.

Noradrenaline, also known as norepinephrine, has a wide range of activities and effects on most brain cell types. Its reuptake from the synaptic cleft heavily relies on the noradrenaline transporter (NET) located in the presynaptic membrane. Here we report the cryo-electron microscopy (cryo-EM) structures of the human NET in both its apo state and when bound to substrates or antidepressant drugs, with resolutions ranging from 2.

View Article and Find Full Text PDF

Background: Major depressive disorder (MDD) is commonly treated with selective serotonin reuptake inhibitors (SSRIs). SSRIs inhibit the serotonin transporter (5-HTT), but the downstream antidepressant mechanism of action of these drugs is poorly understood. The serotonin 1B (5-HT1B) receptor is functionally linked to 5-HTT and 5-HT1B receptor binding and 5-HT1B receptor mRNA is reduced in the raphe nuclei after SSRI administration in primates and rodents, respectively.

View Article and Find Full Text PDF

Major depressive disorder (MDD) is a common and often severe condition that profoundly diminishes quality of life for individuals across ages and demographic groups. Unfortunately, current antidepressant and psychotherapeutic treatments exhibit limited efficacy and unsatisfactory response rates in a substantial number of patients. The development of effective therapies for MDD is hindered by the insufficiently understood heterogeneity within the disorder and its elusive underlying mechanisms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!